Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. If accepted, the Hong Kong-based developer of treatments for cancer and immunological diseases said that the new label indication for savolitinib will be expanded to include treatment-naive patients in China. A treatment-naive patient is someone who has not received any treatment. Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. ‘ More than a third of the world’s lung cancer patients are in China,’ Hutchmed said. Shares in Hutchmed were flat at $16.69 each in London on Thursday morning. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|